Positive Topline Results For Mutant Solid Tumors Reported By Major Medical Company

Immuneering's Breakthrough: Positive Phase 1 Trial Results for IMM-1-104 in RAS-Mutant Solid Tumors.

As an investor it's important to stay updated with major news. Get real-time stock market alerts, news, and research by creating an account here.

In a significant development in the fight against cancer, Immuneering Corporation (Nasdaq: IMRX) recently announced positive topline results from the Phase 1 portion of its Phase 1/2a clinical trial of IMM-1-10…